The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Congenital Heart Disease Market Research Report 2025
Synopsis
The global Congenital Heart Disease market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Congenital Heart Disease is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Congenital Heart Disease is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Congenital Heart Disease in Hospitals and clinics is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Congenital Heart Disease include Pfizer, Novartis, Abbott Laboratories, Roche, GSK, Sanofi, Johnson & Johnson, Medtronic and BD, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Congenital Heart Disease, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Congenital Heart Disease.
Report Scope
The Congenital Heart Disease market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Congenital Heart Disease market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Congenital Heart Disease companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer
Novartis
Abbott Laboratories
Roche
GSK
Sanofi
Johnson & Johnson
Medtronic
BD
Boston Scientific
Merck
Eli Lilly
Mylan
Sun Pharmaceutical
AstraZeneca
Segment by Type
Medication
Surgical Therapy
Segment by Application
Hospitals and clinics
Diagnostic centres
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Congenital Heart Disease companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global Congenital Heart Disease market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Congenital Heart Disease is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Congenital Heart Disease is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Congenital Heart Disease in Hospitals and clinics is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Congenital Heart Disease include Pfizer, Novartis, Abbott Laboratories, Roche, GSK, Sanofi, Johnson & Johnson, Medtronic and BD, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Congenital Heart Disease, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Congenital Heart Disease.
Report Scope
The Congenital Heart Disease market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Congenital Heart Disease market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Congenital Heart Disease companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer
Novartis
Abbott Laboratories
Roche
GSK
Sanofi
Johnson & Johnson
Medtronic
BD
Boston Scientific
Merck
Eli Lilly
Mylan
Sun Pharmaceutical
AstraZeneca
Segment by Type
Medication
Surgical Therapy
Segment by Application
Hospitals and clinics
Diagnostic centres
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Congenital Heart Disease companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Congenital Heart Disease Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Medication
1.2.3 Surgical Therapy
1.3 Market by Application
1.3.1 Global Congenital Heart Disease Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals and clinics
1.3.3 Diagnostic centres
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Congenital Heart Disease Market Perspective (2019-2030)
2.2 Congenital Heart Disease Growth Trends by Region
2.2.1 Global Congenital Heart Disease Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Congenital Heart Disease Historic Market Size by Region (2019-2024)
2.2.3 Congenital Heart Disease Forecasted Market Size by Region (2025-2030)
2.3 Congenital Heart Disease Market Dynamics
2.3.1 Congenital Heart Disease Industry Trends
2.3.2 Congenital Heart Disease Market Drivers
2.3.3 Congenital Heart Disease Market Challenges
2.3.4 Congenital Heart Disease Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Congenital Heart Disease Players by Revenue
3.1.1 Global Top Congenital Heart Disease Players by Revenue (2019-2024)
3.1.2 Global Congenital Heart Disease Revenue Market Share by Players (2019-2024)
3.2 Global Congenital Heart Disease Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Congenital Heart Disease Revenue
3.4 Global Congenital Heart Disease Market Concentration Ratio
3.4.1 Global Congenital Heart Disease Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Congenital Heart Disease Revenue in 2023
3.5 Congenital Heart Disease Key Players Head office and Area Served
3.6 Key Players Congenital Heart Disease Product Solution and Service
3.7 Date of Enter into Congenital Heart Disease Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Congenital Heart Disease Breakdown Data by Type
4.1 Global Congenital Heart Disease Historic Market Size by Type (2019-2024)
4.2 Global Congenital Heart Disease Forecasted Market Size by Type (2025-2030)
5 Congenital Heart Disease Breakdown Data by Application
5.1 Global Congenital Heart Disease Historic Market Size by Application (2019-2024)
5.2 Global Congenital Heart Disease Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Congenital Heart Disease Market Size (2019-2030)
6.2 North America Congenital Heart Disease Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Congenital Heart Disease Market Size by Country (2019-2024)
6.4 North America Congenital Heart Disease Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Congenital Heart Disease Market Size (2019-2030)
7.2 Europe Congenital Heart Disease Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Congenital Heart Disease Market Size by Country (2019-2024)
7.4 Europe Congenital Heart Disease Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Congenital Heart Disease Market Size (2019-2030)
8.2 Asia-Pacific Congenital Heart Disease Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Congenital Heart Disease Market Size by Region (2019-2024)
8.4 Asia-Pacific Congenital Heart Disease Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Congenital Heart Disease Market Size (2019-2030)
9.2 Latin America Congenital Heart Disease Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Congenital Heart Disease Market Size by Country (2019-2024)
9.4 Latin America Congenital Heart Disease Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Congenital Heart Disease Market Size (2019-2030)
10.2 Middle East & Africa Congenital Heart Disease Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Congenital Heart Disease Market Size by Country (2019-2024)
10.4 Middle East & Africa Congenital Heart Disease Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Detail
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Congenital Heart Disease Introduction
11.1.4 Pfizer Revenue in Congenital Heart Disease Business (2019-2024)
11.1.5 Pfizer Recent Development
11.2 Novartis
11.2.1 Novartis Company Detail
11.2.2 Novartis Business Overview
11.2.3 Novartis Congenital Heart Disease Introduction
11.2.4 Novartis Revenue in Congenital Heart Disease Business (2019-2024)
11.2.5 Novartis Recent Development
11.3 Abbott Laboratories
11.3.1 Abbott Laboratories Company Detail
11.3.2 Abbott Laboratories Business Overview
11.3.3 Abbott Laboratories Congenital Heart Disease Introduction
11.3.4 Abbott Laboratories Revenue in Congenital Heart Disease Business (2019-2024)
11.3.5 Abbott Laboratories Recent Development
11.4 Roche
11.4.1 Roche Company Detail
11.4.2 Roche Business Overview
11.4.3 Roche Congenital Heart Disease Introduction
11.4.4 Roche Revenue in Congenital Heart Disease Business (2019-2024)
11.4.5 Roche Recent Development
11.5 GSK
11.5.1 GSK Company Detail
11.5.2 GSK Business Overview
11.5.3 GSK Congenital Heart Disease Introduction
11.5.4 GSK Revenue in Congenital Heart Disease Business (2019-2024)
11.5.5 GSK Recent Development
11.6 Sanofi
11.6.1 Sanofi Company Detail
11.6.2 Sanofi Business Overview
11.6.3 Sanofi Congenital Heart Disease Introduction
11.6.4 Sanofi Revenue in Congenital Heart Disease Business (2019-2024)
11.6.5 Sanofi Recent Development
11.7 Johnson & Johnson
11.7.1 Johnson & Johnson Company Detail
11.7.2 Johnson & Johnson Business Overview
11.7.3 Johnson & Johnson Congenital Heart Disease Introduction
11.7.4 Johnson & Johnson Revenue in Congenital Heart Disease Business (2019-2024)
11.7.5 Johnson & Johnson Recent Development
11.8 Medtronic
11.8.1 Medtronic Company Detail
11.8.2 Medtronic Business Overview
11.8.3 Medtronic Congenital Heart Disease Introduction
11.8.4 Medtronic Revenue in Congenital Heart Disease Business (2019-2024)
11.8.5 Medtronic Recent Development
11.9 BD
11.9.1 BD Company Detail
11.9.2 BD Business Overview
11.9.3 BD Congenital Heart Disease Introduction
11.9.4 BD Revenue in Congenital Heart Disease Business (2019-2024)
11.9.5 BD Recent Development
11.10 Boston Scientific
11.10.1 Boston Scientific Company Detail
11.10.2 Boston Scientific Business Overview
11.10.3 Boston Scientific Congenital Heart Disease Introduction
11.10.4 Boston Scientific Revenue in Congenital Heart Disease Business (2019-2024)
11.10.5 Boston Scientific Recent Development
11.11 Merck
11.11.1 Merck Company Detail
11.11.2 Merck Business Overview
11.11.3 Merck Congenital Heart Disease Introduction
11.11.4 Merck Revenue in Congenital Heart Disease Business (2019-2024)
11.11.5 Merck Recent Development
11.12 Eli Lilly
11.12.1 Eli Lilly Company Detail
11.12.2 Eli Lilly Business Overview
11.12.3 Eli Lilly Congenital Heart Disease Introduction
11.12.4 Eli Lilly Revenue in Congenital Heart Disease Business (2019-2024)
11.12.5 Eli Lilly Recent Development
11.13 Mylan
11.13.1 Mylan Company Detail
11.13.2 Mylan Business Overview
11.13.3 Mylan Congenital Heart Disease Introduction
11.13.4 Mylan Revenue in Congenital Heart Disease Business (2019-2024)
11.13.5 Mylan Recent Development
11.14 Sun Pharmaceutical
11.14.1 Sun Pharmaceutical Company Detail
11.14.2 Sun Pharmaceutical Business Overview
11.14.3 Sun Pharmaceutical Congenital Heart Disease Introduction
11.14.4 Sun Pharmaceutical Revenue in Congenital Heart Disease Business (2019-2024)
11.14.5 Sun Pharmaceutical Recent Development
11.15 AstraZeneca
11.15.1 AstraZeneca Company Detail
11.15.2 AstraZeneca Business Overview
11.15.3 AstraZeneca Congenital Heart Disease Introduction
11.15.4 AstraZeneca Revenue in Congenital Heart Disease Business (2019-2024)
11.15.5 AstraZeneca Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
